Labcorp Expands Oncology Portfolio to Improve Patient Care and Advance Cancer Research
- Introduction of comprehensive new NGS panels for blood cancers offering broader genomic coverage
- Global expansion of Labcorp Plasma Focus to Geneva and Shanghai, enabling consistent testing across regions
- Launch of enhanced digital pathology platform with AI-driven interpretation capabilities
- Addition of HRD testing to OmniSeq INSIGHT for better identification of suitable patients for targeted therapies
- None.
Insights
Labcorp's expanded oncology testing portfolio strengthens their market position and creates new revenue opportunities in precision medicine.
Labcorp's comprehensive expansion of its oncology testing capabilities represents a significant strategic advancement in the precision oncology market. The company is intelligently targeting both clinical diagnostics and biopharma services—two high-growth segments within laboratory medicine.
The new NGS panels for hematologic malignancies and the Rapid AML Panel address critical clinical needs for faster, more accurate diagnosis of blood cancers. These advanced panels will likely improve patient outcomes through earlier intervention and more targeted treatment selection, while simultaneously creating new revenue streams for Labcorp in the specialized oncology testing market.
Particularly noteworthy is the addition of homologous recombination deficiency (HRD) testing to their OmniSeq INSIGHT platform. This capability directly connects to the expanding market for PARP inhibitors in ovarian cancer treatment, effectively positioning Labcorp at the intersection of companion diagnostics and personalized therapy selection.
The global expansion of Labcorp Plasma Focus and Tissue Complete services to Switzerland and China demonstrates smart international growth, enhancing their ability to support global clinical trials with standardized testing methodologies. This approach solves a significant pain point for pharmaceutical companies running multinational studies where testing inconsistency often creates regulatory complications.
The enhanced digital pathology platform utilizing Leica Biosystems technology and Proscia's Concentriq system is particularly forward-looking. This investment in digital infrastructure creates the foundation for AI-driven diagnostic capabilities that will likely become a competitive differentiator as computational pathology continues to evolve.
Overall, these developments strengthen Labcorp's competitive position against rivals like Quest Diagnostics and specialized oncology testing firms, while establishing new revenue opportunities in the rapidly growing precision oncology market.
New test offerings target solid tumors and hematologic malignancies
Enhanced biopharma services support accelerated clinical trials and companion diagnostic development
"Labcorp is committed to serving as the trusted partner for advanced testing at every stage of cancer care," said Shakti Ramkissoon, M.D., Ph.D., vice president and medical lead for oncology at Labcorp. "Our expanded portfolio and integrated solutions provide our partners with the tools and insights they need to accelerate development programs and drive meaningful improvements in patient outcomes."
Diagnostics: New Solutions for Solid Tumor and Hematologic Malignancies
To improve patient access to testing and identify those who may be eligible for targeted therapies, Labcorp is announcing:
- Availability of new NGS panels for myeloid, lymphoid and pan-heme indications: These new panels offer broader genomic coverage and more clinically actionable insights for patients with hematologic malignancies, helping oncologists and pathologists navigate complex diagnoses and guide treatment decisions with greater speed and clarity.
- The launch of a Rapid AML Panel, enhancing Labcorp's comprehensive test menu for acute myeloid leukemia: This panel will enable providers to make more timely, informed treatment decisions.
- Expansion of capabilities to OmniSeq® INSIGHT: Labcorp's pan-solid tumor profiling test will soon include homologous recombination deficiency (HRD) testing. The addition of HRD testing will help identify patients with ovarian cancer who are most likely to benefit from targeted therapies such as PARP inhibitors or who may be eligible for clinical trials.
- Expanded FDA-approved companion diagnostics: Additions include the categorization of HER2-low and HER2-ultralow subtypes in the HER2 IHC test for patients with breast cancer and the VENTANA® MET (SP44) RxDx Assay for patients with non-squamous non-small cell lung cancer.
- Enabling digital pathology advancements for anatomic pathology with further updates scheduled for 2025.
Biopharma Laboratory Services: Accelerating Clinical Trials and Companion Diagnostic Development
To support global trial consistency and enhance collaboration with the company's biopharma customers, Labcorp is also announcing:
- Global expansion of Labcorp® Plasma Focus™: Labcorp will now offer Labcorp Plasma Focus, a solid tumor liquid biopsy test, through its
Geneva, Switzerland andShanghai, China sites. Labcorp Plasma Focus complements the recent global expansion of Labcorp Tissue® Complete, a tissue-based comprehensive genomic profiling assay of over 500 genes for pan-solid tumors. Together, the global availability of these assays enables consistent, high-quality testing across regions, reducing variability in results and streamlining workflows for biopharma partners. - Enhanced digital pathology platform for clinical trials: Labcorp has launched an enhanced digital pathology platform across its global central labs. Utilizing Leica Biosystems Aperio GT450 scanners and Proscia's Concentriq LS image management system, the platform offers scalable, file-agnostic infrastructure to support scanning, archival and companion diagnostic development. It enables real-time global peer review and delivers more accurate, actionable insights with the ability to integrate high-volume image analysis and leverage AI-driven interpretation.
Labcorp at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting
Labcorp will present new research at the 2025 ASCO® Annual Meeting, May 30 – June 3 in Chicago. To learn more, or to connect with Labcorp at ASCO, visit https://oncology.labcorp.com/2025-asco-annual-meeting
For more information about Labcorp's Oncology solutions, contact us at https://oncology.labcorp.com/contact-us
About Labcorp
Labcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company's nearly 70,000 employees serve clients in approximately 100 countries, provided support for more than
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements, including, but not limited to, statements with respect to the expected utility and benefits to patients and customers of the company's enhanced oncology offerings and anticipated future expansions to those offerings.
Each of the forward-looking statements is subject to change based on various important factors, many of which are beyond the company's control. These factors, in some cases, have affected and in the future (together with other factors) could affect the company's ability to implement the company's business strategy, and actual results could differ materially from those suggested by these forward-looking statements. As a result, readers are cautioned not to place undue reliance on any of the forward-looking statements.
The company has no obligation to provide any updates to these forward-looking statements even if its expectations change. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. Further information on potential factors, risks and uncertainties that could affect operating and financial results is included in the company's most recent Annual Report on Form 10-K under the heading RISK FACTORS and in the company's other filings with the SEC. The information in this press release should be read in conjunction with a review of the company's filings with the SEC including the information in the company's most recent Annual Report on Form 10-K under the heading "MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS".
View original content to download multimedia:https://www.prnewswire.com/news-releases/labcorp-expands-oncology-portfolio-to-improve-patient-care-and-advance-cancer-research-302469392.html
SOURCE Labcorp
FAQ
What new oncology tests has Labcorp (LH) added to its portfolio in 2025?
How is Labcorp expanding its global presence in oncology testing?
What digital pathology improvements has Labcorp implemented in 2025?
What new companion diagnostics has Labcorp introduced for cancer patients?
How will Labcorp's new HRD testing capability benefit cancer patients?
